



HAL
open science

Clinical and pathological dermatological features of deficiency of adenosine deaminase 2: A multicenter, retrospective, observational study

François Chasset, Antoine Fayand, Philippe Moguelet, Floriane Kouby, Axelle Bonhomme, Nathalie Franck, Gabrielle Goldman-Lévy, Sylvie Fraitag, Annick Barbaud, Viviane Queyrel, et al.

► To cite this version:

François Chasset, Antoine Fayand, Philippe Moguelet, Floriane Kouby, Axelle Bonhomme, et al.. Clinical and pathological dermatological features of deficiency of adenosine deaminase 2: A multicenter, retrospective, observational study. *Journal of The American Academy of Dermatology*, 2020, 83, pp.1794 - 1798. 10.1016/j.jaad.2020.03.110 . hal-03492768

HAL Id: hal-03492768

<https://hal.science/hal-03492768>

Submitted on 21 Nov 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Clinical and pathological dermatological features of Deficiency of Adenosine Deaminase 2:**
2 **Multicenter retrospective observational study**

3 François Chasset, MD^{1*}, Antoine Fayand, MD^{2*}, Philippe Moguelet, MD³, Floriane Kouby, MD¹,
4 Axelle Bonhomme, MD⁴, Nathalie Franck, MD⁵, Gabrielle Goldman-lévy, MD⁶, Sylvie Fraitag MD⁷,
5 Annick Barbaud, MD, PhD¹, Viviane Queyrel, MD⁸, Isabelle Touitou, MD, PhD⁹, Guilaine Boursier,
6 PharmD, PhD⁹, Guillaume Sarrabay, MD⁹, Stéphanie Ducharme-Benard, MD^{2,10}, Nicolas Dupin MD,
7 PhD⁵, Camille Francès MD¹, Didier Bessis MD, PhD¹¹, Sophie Georgin-Lavialle MD, PhD²; Groupe
8 d'étude des maladies systémiques en dermatologie (EMSED) and Centre de référence des maladies
9 auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA)

10 ¹Sorbonne Université, Faculté de Médecine, AP-HP, Service de Dermatologie et Allergologie, Hôpital
11 Tenon, F-75020 Paris, France

12 ²Sorbonne Université, Faculté de Médecine, AP-HP, Hôpital Tenon, Service de médecine interne,
13 Centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire
14 (CEREMAIA), Paris, France

15 ³Sorbonne Université, Faculté de Médecine Sorbonne Université, AP-HP, Service d'anatomo-
16 pathologie, Hôpital Tenon, F-75020 Paris, France

17 ⁴Metz-Thionville Regional Hospital, Dermatology Department, Metz, France

18 ⁵Université Paris Descartes, AP-HP, Service de dermatologie, Hôpital Cochin, F-75013, Paris

19 ⁶Université Paris Descartes, AP-HP, Service d'anatomo-pathologie, Hôpital Cochin, F-75013, Paris

20 ⁷AP-HP, Hôpital Necker-Enfants-Malades, Department of Pathology, Paris, France

21 ⁸CHU Nice, L'Archet hospital, 151 Route de St Antoine, 06200 Nice, France

22 ⁹CHU Montpellier, Univ Montpellier, Laboratory of Rare and Autoinflammatory Genetic Diseases and
23 CEREMAIA, Montpellier, France

24 ¹⁰Service de Médecine Interne, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada

25 ¹¹Department of Dermatology, Saint-Eloi Hospital and Montpellier University Hospital, Montpellier,
26 France.

27 **Corresponding author & reprint requests:**

28 François Chasset, MD, Sorbonne université, AP-HP, Service de Dermatologie et d'Allergologie,
29 Hôpital Tenon, 4 rue de la Chine 75970 Paris CEDEX 20, France

30 Phone number: (+33156 01 75 47). Fax number: (+331 56 01 72 32)

31 Email: francois.chasset@aphp.fr

32 **Conflict of interest:** None, **Funding sources:** None, **IRB status:** not necessary

33 * contributed equally to the work and shared the first authorship

34 **Words count:** 508, **Tables count** 1: **Figures count:** 1, **Supplemental Table: 1** (available at DOI:
35 10.17632/xd9mp9tn3x.1)

36 *Dear Editor*, Adenosine deaminase 2 deficiency (DADA2) is a monogenic autoinflammatory disease
37 associated with *ADA2* mutations¹.

38 DADA2 diagnosis remains hard given its variable clinical presentation². Although no tests are
39 commercially available, serum *ADA2* activity measurement can help secure the diagnosis which is
40 confirmed by *ADA2* sequencing. Recently, Rama *et al.* proposed a decision tree for the genetic
41 diagnosis of DADA2 based on prerequisites including among others, cutaneous manifestations.
42 However, no study has specifically described DADA2's dermatological spectrum. Furthermore,
43 pathological findings on skin biopsies have rarely been reported^{1,3}, and specific histological features
44 remain to be determined. We conducted a multicenter retrospective study with assessment of clinical
45 and pathological dermatological findings among 8 french DADA2 patients.

46 Cutaneous polyarteritis nodosa (cPAN) was defined as fibrinoid necrotizing vasculitis affecting the
47 small arteries and arterioles ($\geq 300\mu\text{m}$) in the panniculus and dermal-subcutaneous junction as
48 described by Ishibashi and Chen in a 4-stage process⁴ with exclusion after clinicopathologic
49 correlation of differential diagnoses particularly antineutrophil cytoplasmic antibody-associated
50 vasculitis.

51 DADA2's main clinical features are presented in **Table 1** and detailed in **Supplemental Table 1**.
52 Median age at first symptom was 9.5 [range 0.5-29] years, whereas median age at diagnosis was 25.5
53 [range 6-38] years.

54 Cutaneous manifestations (**Figure 1**) were the first symptoms of DADA2 in 3/8 patients. Livedo was
55 observed in all cases and was of the racemosa subtype in 7/8 patients, with mostly a large pattern
56 (6/8). It involved both legs and arms in all cases, extending to the abdomen or trunk in 3 cases. It was
57 palpable in one patient. Other cutaneous manifestations included leg nodules (n=7, non-specific or
58 erythema nodosum-like lesions), leg ulcers (n=3), Raynaud's phenomenon (n=2), "atrophie blanche"
59 (n=2), digital necrosis (n=2), erythematous feet papules (n=1), and psoriasis (n=1).

60 Overall, 12 skin biopsies from 7 patients were reviewed (**Table 1 and Figure 1**). cPAN was identified
61 in 4/7 patients. In patients n°3 and 4, skin biopsies revealed thrombosis of dermal and/or hypodermal

62 capillaries, without vasculitis. While subacute cPAN was also observed in skin biopsy from patient
63 n°4, patient n°3 had only isolated thrombosis.

64 Here, we portrayed the dermatological spectrum of DADA2 patients thus contributing to its better
65 recognition. Livedo was observed in all cases, was mostly racemosa, extensive with a large reticular
66 pattern. Differentiating between DADA2 and antiphospholipid-negative Sneddon's syndrome (as in
67 patient n°4) may be challenging since both may present with livedo and strokes⁵. While skin biopsies
68 of DADA2 patients most frequently revealed vasculitis, 2 patients in our series showed capillary
69 thrombosis such as in Sneddon's syndrome⁵.

70 Importantly, 3/7 patients did not have vasculitis on skin biopsy. The site and depth of biopsy is
71 probably important. Indeed, while we found non-specific features in 2 superficial biopsies of livedo
72 without analyzable hypodermis, cPAN was more frequently identified in biopsies taken from nodules.

73 Overall, livedo racemosa with a large branch pattern, nodules or ulcerations in a context of
74 neurovascular events, recurrent fever, low IgM levels and pediatric onset, are suggestive of DADA2.
75 While cPAN on skin biopsy is suggestive of DADA2, its absence or the presence of thrombotic
76 features does not exclude the diagnosis.

77 **Acknowledgement:** None

78

79

80

81

82

83

84

85

86 **Abbreviations and acronyms**

87 DADA2: Adenosine deaminase 2 deficiency

88 cPAN: Cutaneous polyarteritis nodosa

89 CRP: C-reactive protein

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

110 **References**

- 111 1. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with
112 mutations in ADA2. *N Engl J Med*. 2014;370(10):911-920. doi:10.1056/NEJMoa1307361
- 113 2. Rama M, Duflos C, Melki I, et al. A decision tree for the genetic diagnosis of deficiency of
114 adenosine deaminase 2 (DADA2): a French reference centres experience. *Eur J Hum Genet*
115 *EJHG*. 2018;26(7):960-971. doi:10.1038/s41431-018-0130-6
- 116 3. Gonzalez Santiago TM, Zavialov A, Saarela J, et al. Dermatologic Features of ADA2 Deficiency
117 in Cutaneous Polyarteritis Nodosa. *JAMA Dermatol*. 2015;151(11):1230-1234.
118 doi:10.1001/jamadermatol.2015.1635
- 119 4. Ishibashi M, Chen K-R. A morphological study of evolution of cutaneous polyarteritis nodosa.
120 *Am J Dermatopathol*. 2008;30(4):319-326. doi:10.1097/DAD.0b013e3181766190
- 121 5. Francès C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or
122 without antiphospholipid antibodies. A comparative study in 46 patients. *Medicine (Baltimore)*.
123 1999;78(4):209-219.

124

125

126

127 .

128








Table 1. Main clinical and pathological skin features of the 8 French DADA2 patients

Patient/ Biopsy N	Skin manifestations	Extra-cutaneous manifestations	Site of biopsy	Thrombosis	Type of vessels	Vasculitis	Type of vessels	Other findings
1/1	-Livedo racemosa -Perimalleolar ulcers - Raynaud's phenomenon -"Atrophie blanche"	Recurrent fever, increased CRP level, abdominal pain, peripheral neuropathy	Leg ulcer	No	-	No	-	Pyogenic granuloma
2/1	-Livedo racemosa	Recurrent fever, arthralgia, myalgia, hepatitis	Livedo of the leg	No	-	No	-	Slight perivenular lymphocytic infiltrate in hypodermis
3/1	-Livedo racemosa -Leg nodules	Anemia, increased CRP level	Nodule of the leg	Yes	Hypodermal capillaries	No	-	
3/2	-Perimalleolar ulcers -"Atrophie blanche"		Livedo of an ankle	Yes	Dermal capillaries	No	-	
3/3			Livedo of the trunk	No	-	No	-	Non-specific inflammation
3/4			Nodule of an ankle	Yes	Dermal and hypodermal capillaries	No	-	
3/5			Nodule of the leg	Yes	Dermal and hypodermal capillaries	No	-	
4/1	-Livedo racemosa -Leg nodules -Digital necrosis -Raynaud's phenomenon -Erythematous feet papules	Recurrent fever, recurrent ENT infections, cerebral infarct, hypogammaglobulinemia	Livedo of the thigh (infiltrated zone)	Yes	Dermal and hypodermal capillaries	Subacute cPAN	Deep dermis medium- sized artery	-

5/1	-Livedo racemosa -Ulcerated leg nodules -Leg nodules -Psoriasis	Recurrent fever, increased CRP level, pericarditis, myocarditis, intestinal vasculitis, renal microaneurysm, peripheral neuropathy, TIA > death	Nodule of the leg	Yes	Deep dermis medium-sized artery	Acute cPAN	Deep dermis medium-sized artery	
6	-Livedo reticularis	Increased CRP level, ischemic strokes, hepatosplenomegaly, low IgM level, negative vaccinal serologies	No biopsy					
7/1	-Livedo racemosa -Leg nodules	Recurrent fever, increased CRP level, arthralgia, abdominal pain, hepatosplenomegaly, epilepsy	Nodule of the leg	No	-	Reparative cPAN	Deep dermis medium-sized artery	
7/2			Nodule of the leg	No		No	Septal panniculitis	
8/1	-Livedo racemosa -Digital necrosis -Leg nodules	Recurrent fever, increased CRP level, Ischemic strokes, abdominal pain, psychosis, pericarditis	Nodule of the leg	No		Subacute cPAN	Deep dermis medium-sized artery	

CRP: C-reactive protein, ENT: Ear, nose, and throat; TIA: Transient ischemic attack, cPAN: cutaneous periarteritis nodosa, Definition of cPAN stages by Ishibashi and Chen: Acute : endothelial loss and fibrin thrombi with neutrophil infiltration without obvious internal elastic lamina disruption and medial fibrinoid necrosis; Subacute: mixed cell infiltrates showing a unique intimal target-like fibrinoid necrosis with fibrinoid leakage extending through the disrupted sites of the internal elastic lamina to the media; Reparative: intimal fibroblastic proliferation and perivascular neovascularization with predominant infiltrates of histiocytes and lymphocytes; Healed: minimal cellular inflammation with occlusive intimal thickening. Thrombosis was defined as complete occlusion of the vascular lumen by a cluster of fibrin